MARKET

TVGNW

TVGNW

Tevogen Bio
NASDAQ
0.0489
-0.0010
-2.00%
Closed 15:51 06/12 EDT
OPEN
0.0425
PREV CLOSE
0.0499
HIGH
0.0489
LOW
0.0359
VOLUME
5.14K
TURNOVER
--
52 WEEK HIGH
0.0800
52 WEEK LOW
0.0253
MARKET CAP
--
P/E (TTM)
-0.0070
1D
5D
1M
3M
1Y
5Y
1D
Tevogen Creates Healthcare Services Initiative Led By VP Of Strategic Initiatives William Keane On Interim Basis
Benzinga · 3d ago
Tevogen launches healthcare services initiative, weighs MSO and CRO acquisitions targeting $100 million annual revenue
PUBT · 3d ago
Tevogen Announces Formation of a Healthcare Services Initiative
Barchart · 3d ago
Weekly Report: what happened at TVGN last week (0601-0605)?
Weekly Report · 4d ago
Weekly Report: what happened at TVGN last week (0525-0529)?
Weekly Report · 06/01 10:37
Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest
NASDAQ · 05/29 06:27
Tevogen Advances Strategic Acquisition Plans With Potential To Add $100 Million In Annual Revenue
NASDAQ · 05/29 05:25
*Tevogen Sees $100M in Combined Annual Revenue if Initiatives Consummated
Dow Jones · 05/28 16:33
More
About TVGNW
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.

Webull offers Tevogen Bio Holdings Inc stock information, including NASDAQ: TVGNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVGNW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVGNW stock methods without spending real money on the virtual paper trading platform.